Business Context and Reporting Period
This Form 8-K was filed by Dare Bioscience, Inc. on January 17, 2024. The Company is a Delaware corporation with its principal executive offices in San Diego, California. Its common stock trades on the Nasdaq Capital Market under the symbol "DARE".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status rather than financial performance.
Material Changes
On January 17, 2024, the Nasdaq Listing Qualifications Department notified the Company that it failed to regain compliance with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)). The Company's stock had traded below the $1.00 per share minimum for 30 consecutive business days. Consequently, the Company's common stock is now subject to delisting from the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Delisting Hearing: The Company intends to timely request a hearing before the Nasdaq Hearing Panel. This request will stay the delisting process pending the Panel's decision.
- Timeline: Hearings are typically scheduled 30 to 45 days after the request, with decisions issued within 30 days of the hearing. However, the Company notes that timelines could be shorter than expected, which may be unfavorable.
- Risks: There is no assurance that the Company will be successful at the hearing or that it will maintain its listing on the Nasdaq Capital Market.
- Forward-Looking Statements: The report contains forward-looking statements regarding the hearing schedule and decision timing, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the current status of the Company's request for a hearing with the Nasdaq Hearing Panel.
- Monitor the Company's stock price to determine if it has met the $1.00 minimum bid price requirement.
- Review any subsequent filings for the outcome of the Nasdaq hearing and the final listing decision.
- Assess the potential impact of delisting on the liquidity and trading venue of the Company's common stock.